Ecleralimab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameEcleralimab
Drug Alias NameCSJ-117NOV-14
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment
Mechanisms of ActionThymic stromal lymphopoietin inhibitors
TargetsThymic stromal lymphopoietin
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[16] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag
Inactive CompaniesN/A
Active IndicationsPulmonary Disease, Chronic Obstructive
Inactive IndicationsAsthma

Other Information

ATC CodeN/A
Related LinksN/A